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of renal autoregulation. In animal mod-
els, this autoregulatory impairment is 
associated with a relative lack of renal 
protection compared with the magnitude 
of blood pressure reduction observed.5,6 
Consequently, there is a failure to maxi-
mally protect against renal parenchymal 
changes with such agents unless systolic 
blood pressure is lowered well below the 
range of 100–105 mm Hg.7
In contrast, T-type calcium channels 
are expressed in both the afferent 
(preglomerular) and the eﬀerent (post-
glomerular) arterioles,8 and hence, 
their inhibition may overcome the 
eﬀect of increased glomerular pressure 
transmission, as both arterioles would 
be dilated in the additional presence 
of renin–angiotensin system blockade. 
Efonidipine is a dihydropyridine T-type 
calcium channel antagonist that has 
been extensively studied in regard to 
renal hemodynamics9 and, in rat mod-
els, demonstrated signiﬁcantly greater 
reduction in intraglomerular pressure 
and proteinuria than L-channel dihydro-
pyridine despite similar blood pressure-
lowering eﬀects.10,11
The study by Sugano and colleagues12 
(this issue) adds to our understanding 
of the factors that contribute to changes 
within the renal vasculature in a rat model 
of renal insuﬃciency by both efonidipine 
and the R(–) isomer of efonidipine. The 
authors confirm that blockade of the 
T-type calcium channel confers a greater 
hemodynamic protection on the renal 
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These differences translate into different renal hemodynamic effects. 
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surrogate markers of outcome.
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Calcium antagonists comprise two main 
subclasses, dihydropyridines and non-
dihydropyridines. They inhibit two types 
of voltage-dependent channels: a high 
voltage-activated calcium channel includ-
ing P-/Q-, L-, N-, and R-type channels, 
and a low voltage-activated T-type chan-
nel. Calcium antagonists modulate various 
calcium-dependent functions of vascular 
smooth muscle throughout the body as 
well as cardiac myocytes and the conduc-
tive tissues of the heart. The distribution of 
these channels varies throughout the vas-
culature and results in diﬀerences in kid-
ney function when inhibited (Figure 1). 
These differences account, in part, for 
some of the observed clinical diﬀerences 
in antiproteinuric response and relative 
degrees of tissue protection.1–4
Nifedipine, diltiazem, and verapamil 
serve as the prototypic agents for the 
dihydropyridine, benzothiazepine, and 
phenylalkylamine classes of L-channel 
calcium antagonists, respectively. The 
L channel is located primarily on the aﬀer-
ent (preglomerular) arteriole and hence, 
when antagonized, results in impairment 
microvasculature than the L-type cal-
cium channel blockade and extend our 
previous knowledge by demonstrating 
non-hemodynamic eﬀects of this agent, 
including inhibition of Rho-kinase activity 
in response to transforming growth fac-
tor-β, reduced tubulointerstitial ﬁbrosis, 
and epithelial–mesenchymal transition. 
This study further distinguishes efo-
nidipine as a calcium antagonist with not 
only a unique hemodynamic proﬁle but 
also cellular eﬀects not seen with other 
dihydropyridine agents in the class.13
Although the L-channel dihydropyridine 
calcium antagonists have been extensively 
studied in humans with regard to proteinu-
ric kidney disease progression, they have 
failed to show the outcome beneﬁt noted 
with blockers of the renin–angiotensin–
aldosterone system.2,14 Moreover, the 
beneﬁt of the dihydropyridine calcium 
antagonists in this setting is not as great as 
that of the non-dihydropyridine agents.2 
An early systematic review reported by 
Kloke et al. showed that calcium antago-
nists are eﬀective antihypertensive agents 
but are of uncertain value in patients with 
proteinuria and elevated creatinine.15 In 
subsequent randomized blinded outcome 
trials of people with proteinuric kidney 
disease, progressive increases in proteinu-
ria and a more rapid decline in kidney 
function were noted in patients treated 
with dihydropyridine calcium antago-
nists compared with those treated with 
angiotensin-converting enzyme (ACE) 
inhibitors or angiotensin receptor block-
ers.16,17 In the African American Study 
of Kidney Disease and Hypertension and 
the Irbesartan Diabetic Nephropathy Trial, 
the dihydropyridine calcium antagonist 
amlodipine failed to slow decline in kidney 
function or mitigate increases in proteinu-
ria in patients with hypertension and pro-
teinuric nephropathy as compared with 
an ACE inhibitor or angiotensin receptor 
blocker regimen.16,17 A recent systematic 
review of 28 randomized trials evaluating 
renal outcomes in hypertensive patients 
with or without diabetes found similar 
blood pressure lowering with diﬀerences in 
antiproteinuric eﬀects between dihydropy-
ridine and non-dihydropyridine calcium 
antagonists.2 Analysis of the blood pressure 
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data (n = 1,338) and kidney function data 
(n = 510) showed signiﬁcant diﬀerences 
in proteinuria reduction between groups 
(+2% with dihydropyridines versus –30% 
with non-dihydropyridines, P = 0.01). 
After adjustment for blood pressure, sam-
ple size, and study duration, a trend per-
sisted in favor of proteinuria reduction for 
the non-dihydropyridines. A secondary 
analysis supported the beneﬁt for nephro-
pathy progression of non-dihydropyridines 
with or without concurrent ACE inhibitor 
or angiotensin receptor blocker therapy.2
Unfortunately, very few human studies 
have been done with the T-type channel 
calcium antagonists, and currently no 
clinical outcome data exist. The largest 
randomized human study to date is an 
open-label prospective trial that evalu-
ated 68 hypertensive patients with chronic 
kidney disease, that is, serum creatinine 
greater than 1.5 mg/dl over the span of 
48 weeks. The authors compared the 
eﬀects on blood pressure and proteinuria 
reduction of the dihydropyridine T-type 
calcium channel antagonist efonidipine 
(mean dose of 38 mg per day at study’s 
end) versus various ACE inhibitor mono-
therapy treatments (mean dose of enal-
april, lisinopril, and imidapril was 8 mg 
per day, 11 mg per day, and 5 mg per day, 
respectively, at study’s end).10 Both classes 
of antihypertensive agents reduced blood 
pressure and urinary protein excretion to 
a similar extent in a cohort of patients with 
a baseline proteinuria greater than 1 g per 
day. This preliminary observation indi-
cates that efonidipine may also slow pro-
gression of proteinuric kidney disease to 
an extent similar to that achieved by ACE 
inhibitors, although this needs conﬁrma-
tion in future clinical studies. A ﬁxed-dose 
combination of efonidipine with a blocker 
of the renin–angiotensin system may pro-
vide an additional tool in the armamen-
tarium to treat hypertensive proteinuric 
kidney disease since each agent has com-
plementary intra-renal hemodynamic as 
well as systemic blood pressure lowering 
eﬀects. All this needs conﬁrmation in ran-
domized clinical trials.
Efonidipine is used primarily in Japan 
and has not been available in the United 
States, Australia, or Europe. It should 
be appreciated, however, that there 
are differential benefits for proteinuria 
reduction with non-dihydropyridine rela-
tive to dihydropyridine agents in the subset 
of patients with advanced proteinuric kid-
ney disease. This diﬀerential eﬀect may 
result in a slower decline in kidney func-
tion,2,14 although this has not been proven. 
On the basis of the recommendations of 
the Kidney Disease Outcomes Quality 
Initiative (KDOQI) blood pressure and 
diabetes guidelines, non-dihydropyridine 
calcium antagonists in conjunction with 
an ACE inhibitor or angiotensin recep-
tor blocker are preferable in hypertensive 
patients with proteinuria greater than 
300 mg per day, as well as those with 
impaired kidney function.18,19
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Figure 1 | Location of L and T channels in the glomerulus. MD, macula densa; BS, Bowman’s space.
